San Francisco, March 28, 2022 – Recardio Inc., a late stage clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, is participating at the BIO-Europe Spring 2022.
The conference will be held digitally this year and is an international forum to promote business development between pharmaceutical, financial and biotechnology companies. The event is Europe’s largest partnering conference serving the global biotech industry. At this conference leading decision makers of the biotechnology, pharmaceutical and financial industry employed at emerging companies meet annually.
Recardio is presenting its latest advancements from its drug-based regenerative therapy clinical development program and will give a future outlook on new therapies and expansion programs.
The BIO-Europe is taking place from March 28 to 30 2022.
Recardio Inc. is a late clinical-stage life science company focusing on therapies for cardiovascular and other diseases. The company is located in San Francisco, California, and is having its operations in USA and Europe. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor having demonstrated significant effects in activating various chemokines like SDF-1, a protein that is critical for cardiac regeneration resulting in healing cardia tissue after an injury.
Recardio is currently initiating its global pivotal Phase 3 clinical program in acute myocardial infarction for market authorization in major markets and will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases.
In addition, other development programs are in preclinical stage.
For more information, visit: http://www.recardio.eu/ or contact email@example.com